Literature DB >> 33350753

Correlation between tumor marker CA72-4 and prognosis of patients with gastric cancer: A protocol for systematic review and meta-analysis.

Minxia Li1, Fei Xue2, Jie Yang3, Xiaodong Pan4.   

Abstract

BACKGROUND: Gastric cancer is one of the common gastrointestinal tumors, with high recurrence and metastasis rates. Tumor marker tumor marker carbohydrate antigen 72-4 (CA72-4) has been used in the screening and diagnosis of gastric cancer, but whether it can be used as an indicator to monitor the prognosis of gastric cancer remains a great controversy. The purpose of this study was to systematically evaluate the correlation between tumor marker CA72-4 and prognosis of gastric cancer patients.
METHODS: A systematic search was performed by retrieving on English databases (PubMed, Embase, Web of Science, the Cochrane Library) and Chinese databases (China Knowledge Network, Wanfang, Weipu (VIP Information Chinese Journal Service Platform), CBM) of clinical study on the correlation between tumor marker CA72-4 and prognosis of gastric cancer patients. The retrieval time limit was from the establishment of the database to October 2020. Two researchers independently extracted and evaluated the quality of the data in the included study. A meta-analysis was performed using Stata12.0 and RevMan5.3 software.
CONCLUSIONS: This study will compare the correlation between tumor marker CA72-4 and prognosis of gastric cancer patients, so as to provide evidence-based basis for clinicians to select prognostic indicators of gastric cancer. ETHICS AND DISSEMINATION: Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences. OSF REGISTRATION NUMBER: DOI: 10.17605 / OSF.IO / B3AMN.
Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33350753      PMCID: PMC7769321          DOI: 10.1097/MD.0000000000023723

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  21 in total

1.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

2.  Prognostic value of carbohydrate tumor markers and inflammation-based markers in metastatic or recurrent gastric cancer.

Authors:  Qing Wang; Yang Yang; Ya-Ping Zhang; Zhengyun Zou; Xiaoping Qian; Baorui Liu; Jia Wei
Journal:  Med Oncol       Date:  2014-10-26       Impact factor: 3.064

3.  A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis.

Authors:  Milo A Puhan; Holger J Schünemann; Mohammad Hassan Murad; Tianjing Li; Romina Brignardello-Petersen; Jasvinder A Singh; Alfons G Kessels; Gordon H Guyatt
Journal:  BMJ       Date:  2014-09-24

4.  Prognostic significance of tumour markers in Chinese patients with gastric cancer.

Authors:  Xiaowen Liu; Hong Cai; Yanong Wang
Journal:  ANZ J Surg       Date:  2012-09-26       Impact factor: 1.872

5.  The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the "different disease" hypothesis.

Authors:  S A Hundahl; J L Phillips; H R Menck
Journal:  Cancer       Date:  2000-02-15       Impact factor: 6.860

6.  Preoperative hCGbeta and CA 72-4 are prognostic factors in gastric cancer.

Authors:  Johanna Louhimo; Arto Kokkola; Henrik Alfthan; Ulf-Håkan Stenman; Caj Haglund
Journal:  Int J Cancer       Date:  2004-10-10       Impact factor: 7.396

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

Review 8.  Advances in Molecular Biomarkers for Gastric Cancer.

Authors:  Tang-Hui Zheng; Jun-Lin Zhao; Bayasi Guleng
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2015       Impact factor: 1.807

Review 9.  Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with d2 lymphadenectomy.

Authors:  Qiong Yang; Ying Wei; Yan-Xian Chen; Si-Wei Zhou; Zhi-Min Jiang; De-Rong Xie
Journal:  Gastroenterol Res Pract       Date:  2013-10-01       Impact factor: 2.260

Review 10.  Clinical and biological markers in gastric cancer: update and perspectives.

Authors:  Alessandro Cappellani; Antonio Zanghi; Maria Di Vita; Ernesto Zanet; Pierfrancesco Veroux; Bruno Cacopardo; Andrea Cavallaro; Gaetano Piccolo; Emanuele Lo Menzo; Paolo Murabito; Massimiliano Berretta
Journal:  Front Biosci (Schol Ed)       Date:  2010-01-01
View more
  2 in total

1.  Combination of preoperative CA19-9 levels, cell differentiation, and age predicts survival for patients with gastric cancer before surgery.

Authors:  Hui Hui Yin; Meng Qing Xu; Bin Zheng Liu; Lin Tao; Ya Jing Ma; Feng Li; Wen Jie Zhang
Journal:  Medicine (Baltimore)       Date:  2021-12-10       Impact factor: 1.817

2.  Application of serum pepsinogen and carbohydrate antigen 72-4 (CA72-4) combined with gastrin-17 (G-17) detection in the screening, diagnosis, and evaluation of early gastric cancer.

Authors:  Zengbao Lin; Huiqin Bian; Chaoyuan Chen; Wenling Chen; Qiong Li
Journal:  J Gastrointest Oncol       Date:  2021-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.